What Is a Mosaic Embryo and Should You Transfer One?

A mosaic embryo is one whose cells are not genetically uniform: some cells have the expected number of chromosomes, while others carry too many or too few. These embryos sit in a gray zone between the clearly normal (euploid) and clearly abnormal (aneuploid) results that preimplantation genetic testing delivers during IVF. Whether you should transfer one depends on a tangle of factors, from how much mosaicism was detected to whether you have other embryos available, and the science behind the answer is still catching up to the question.

How Mosaicism Happens

Chromosomal problems in embryos can originate at two different stages. Errors during the formation of egg or sperm cells produce uniform aneuploidy, meaning every cell in the resulting embryo inherits the same chromosomal mistake. Mosaicism, by contrast, arises from errors that happen after fertilization, during the early cell divisions of the embryo itself. When a dividing cell fails to sort its chromosomes evenly, one daughter cell ends up with an extra copy and the other with one fewer. The result is an embryo containing two or more genetically distinct cell populations.¹ Because these mitotic errors can occur at different points during development, the proportion of affected cells varies widely. An error at the very first division could affect half the embryo; one occurring several divisions later might affect only a small fraction.²

Researchers distinguish between meiotic errors (which affect the egg or sperm before fertilization) and mitotic errors (which happen after) by looking at how many cells are affected. If all cells in a biopsy show the same abnormality, the error was likely meiotic. If a biopsy shows a mix of normal and abnormal signals, that intermediate pattern points to a mitotic error and flags the embryo as mosaic.³ This distinction matters clinically because uniformly aneuploid embryos are almost never transferred, while mosaic embryos carry a more ambiguous prognosis.

How Testing Detects Mosaicism, and Where It Falls Short

Preimplantation genetic testing for aneuploidy (PGT-A) works by removing a small cluster of cells from the trophectoderm, the outer shell of a blastocyst that eventually becomes the placenta rather than the baby. Those few cells are then analyzed to estimate the chromosomal makeup of the entire embryo. Mosaicism is identified when the genetic signal falls between what you would expect from a fully normal sample and a fully abnormal one. A commonly used convention defines mosaicism as a signal in the range of roughly 30 to 70 percent abnormality; signals above 70 percent are treated as fully aneuploid, and those below 30 percent as normal.³

The technology used for analysis makes a difference. Next-generation sequencing (NGS) detects mosaicism at a significantly higher rate than older platforms. One study found a mosaicism detection rate of about 23 percent with NGS compared with roughly 8 percent using a different array-based method.⁴ That threefold difference means many embryos that would have been classified as simply abnormal under older technology are now landing in the mosaic category, which partly explains why mosaic results feel so much more common to patients today than they did a decade ago.

A fundamental limitation is that the biopsy samples the outer layer, not the inner cell mass (ICM) that actually develops into the fetus. There has been sustained debate about how well a trophectoderm biopsy represents the embryo’s true chromosomal status.⁵ When researchers have compared the two directly, they have found that the concordance is not perfect, but a single trophectoderm biopsy can correctly predict whether the ICM consists of mostly normal or mostly abnormal cells in the majority of cases.⁶ “Majority of cases” is reassuring but not the same as certainty, and this gap is one reason the mosaic category generates so much clinical uncertainty.

The Overestimation Problem

Some researchers argue that a meaningful share of mosaic diagnoses are technical artifacts rather than true biological mosaicism. The thresholds used to define mosaicism are based on models that mix normal and abnormal cells under controlled laboratory conditions. Real trophectoderm biopsies are messier: the amount and quality of DNA varies, and the handful of cells removed may not faithfully reflect the broader embryo. One analysis found that when low-to-mid-range mosaic trophectoderm results were checked against the corresponding inner cell mass, the ICM was predominantly normal, suggesting that the mosaicism call had been an overestimate.⁷ This is a live controversy in the field. It means some embryos labeled mosaic may actually be chromosomally normal, and the mosaic label could be costing patients viable embryos they would have transferred otherwise.

Can Embryos Correct Themselves?

One of the most intriguing findings from recent years is that embryos appear to have built-in mechanisms for dealing with aneuploid cells. Several pathways have been proposed: abnormal cells may be selectively destroyed through programmed cell death, physically excluded from the developing embryo, shunted into the placental tissue rather than the fetal lineage, or corrected through chromosomal rescue events where the extra or missing chromosome is gained or lost to restore a normal count.⁸ In animal models, this kind of selective purging of abnormal cells from the future fetal lineage has been clearly demonstrated. In human embryos, the evidence is more circumstantial. Researchers have observed higher rates of cell death in the inner cell mass than in the trophectoderm, and have identified molecular markers in the fluid inside the blastocyst that suggest apoptosis is actively clearing aneuploid cells before implantation.⁹

Self-correction is not guaranteed. In some embryos, the aneuploid cell lines persist. A case report documented a live birth after mosaic embryo transfer in which the baby carried a nonmosaic partial aneuploidy and uniparental disomy of chromosome 15, a pattern consistent with incomplete trisomy rescue: the embryo tried to correct the extra chromosome but did so imperfectly, leaving both copies inherited from one parent.¹⁰ Cases like this are rare but underscore that self-correction is a probabilistic process, not a reliable failsafe. The clinical picture is further complicated by the question raised earlier: when healthy babies are born from mosaic embryo transfers, is that because the embryo corrected itself, or because the mosaic diagnosis was an overestimate in the first place? Both are plausible, and at the individual level, you often cannot tell which explanation applies.

Live Birth Rates and Pregnancy Outcomes

The headline numbers from clinical studies are consistent: mosaic embryos lead to live births at lower rates than euploid embryos, but not dramatically so. A systematic review and meta-analysis found that mosaic embryos have significantly lower implantation and live birth rates compared with euploid embryos, but that once implantation occurs, miscarriage rates are comparable between the two groups.¹¹ In practical terms, the biggest hurdle for a mosaic embryo is getting past implantation. If it implants, its chances of progressing to a healthy delivery are much closer to those of a euploid embryo.

Individual studies put more specific numbers on the gap. One found a live birth rate of about 47 percent for mosaic transfers versus 59 percent for euploid transfers.¹² A multicenter study reported a lower ongoing or live birth rate of about 27 percent for mosaic transfers, compared with 47 percent for euploid and 35 percent for untested embryos.¹³ A prospective non-selection trial, where embryos were transferred regardless of their PGT-A result, found comparable rates of live birth and miscarriage between euploid embryos and those with low-to-medium levels of mosaicism.¹⁴ The variation across studies reflects differences in how mosaicism is defined, how patients are selected, and whether the comparison group is euploid embryos or untested ones.

Does the Type or Level of Mosaicism Matter?

Not all mosaic results carry the same risk, and clinicians try to stratify them. The two main axes are the level of mosaicism (what percentage of cells appear abnormal) and the type (whether the abnormality involves whole chromosomes or just segments of chromosomes).

On level, one study compared single embryo transfers of low-level versus high-level mosaic embryos and found no significant difference in clinical pregnancy rate or live birth rate, but a substantially higher miscarriage rate with high-level mosaicism: roughly 31 percent compared with about 5 percent for low-level mosaics.¹⁵ The implication is that the embryos implant at similar rates regardless of mosaicism level, but high-level mosaics are more likely to be lost after implantation.

On type, segmental mosaicism (where only a piece of a chromosome is affected rather than the whole thing) appears to carry better outcomes. One study found that segmental mosaic embryos had implantation and live birth rates comparable to euploid embryos.¹⁶ A meta-analysis confirmed this pattern, finding that embryos with only segmental mosaicism had significantly better implantation rates, lower miscarriage rates, and higher ongoing pregnancy or live birth rates than those with whole-chromosome mosaicism.¹⁷

As for which specific chromosome is involved, recent research suggests that the chromosome’s identity matters less than previously thought. After accounting for the severity and type of the abnormality, most apparent chromosome-specific associations with worse outcomes were weakened or disappeared.¹⁸ In other words, the primary drivers of outcome seem to be how much mosaicism is present and what form it takes, not which particular chromosome is affected. That said, certain chromosomes (like 15 and 16) still receive extra caution because of the risk of uniparental disomy if trisomy rescue occurs imperfectly.

How Healthy Are Babies Born from Mosaic Transfers?

This is the question that weighs most heavily on patients, and the data so far is broadly reassuring. The largest dataset comes from an international registry of mosaic embryo transfers that analyzed over 3,000 cases. Of the pregnancies for which postnatal data was available, the vast majority of babies, over 99 percent, were healthy by routine neonatal examination, with no gross abnormalities detected. Prenatal testing results collected across hundreds of pregnancies were predominantly normal as well.¹⁹

These numbers need context. Mosaic embryo transfers are still relatively uncommon compared with euploid transfers, and long-term developmental follow-up data is limited. The babies in these registries have been assessed at birth, not tracked through childhood for subtler developmental or health concerns. Still, the available evidence does not suggest an elevated rate of birth defects or chromosomal syndromes in babies born from mosaic embryo transfers, and this has been a key factor in the field’s gradually warming stance toward considering them for transfer.

How Clinics Prioritize Mosaic Embryos

Professional societies have developed frameworks for deciding which mosaic embryos are the better candidates for transfer, though practices vary. A survey conducted by the European Society of Human Reproduction and Embryology (ESHRE) found that clinics use several criteria to rank mosaic embryos: the level of mosaicism, the type of abnormality (segmental versus whole chromosome versus complex), which specific chromosomes are involved (with particular attention to those associated with viable trisomies or uniparental disomy risks), and how many chromosomes are affected.²⁰ Genetic counseling before any mosaic transfer is considered standard of care.

In general, the hierarchy for transfer priority runs roughly as follows:

Best candidates: Low-level mosaicism affecting a single segmental region
Intermediate: Low-level whole-chromosome mosaicism involving chromosomes not associated with viable syndromes
More caution: High-level mosaicism, multiple chromosomes affected, or chromosomes associated with uniparental disomy risks (such as chromosomes 6, 7, 11, 14, 15, and 20)
Generally avoided: Complex mosaicism involving multiple whole-chromosome abnormalities

These are guidelines, not rules. The decision is always individualized. A patient with no euploid embryos and limited remaining fertility may reasonably choose to transfer a mosaic embryo that a younger patient with many euploid options would set aside.

The Emotional Weight of a Mosaic Result

Qualitative research with patients who receive mosaic PGT-A results reveals a common emotional arc: stress, disappointment, and fear, often compounded by the sense of having invested heavily in testing only to receive an answer that is not clearly yes or no. As one participant in a study put it, learning about a mosaic result felt like the testing had confirmed something was wrong, even though the reality is more nuanced than that.²¹

When researchers tracked what patients actually did after receiving mosaic results, about 30 percent initially chose to go ahead with a mosaic embryo transfer, while roughly 42 percent pursued a new treatment cycle instead. Only about 6 percent discarded their mosaic embryos outright; the rest either moved them to another facility or left them in storage while deciding. Among those who became pregnant from mosaic transfers, a little over half pursued amniocentesis to check the baby’s chromosomes directly.²² The low discard rate suggests that most patients are not willing to give up on mosaic embryos entirely, even when they are uncertain about transferring them right away.

Non-Invasive Testing on the Horizon

Much of the uncertainty around mosaic embryos stems from the fact that a biopsy captures only a snapshot of a few outer-layer cells. Researchers are developing non-invasive alternatives that could sidestep this problem. The most promising approach analyzes cell-free DNA (cfDNA) shed by the embryo into the culture medium it grows in, essentially reading the genetic signals the embryo leaves behind without touching it.²³ In theory, this approach could sample genetic material from a broader cross-section of the embryo’s cells rather than just one spot on the outer shell, giving a more representative picture. It could also be simpler, safer, and cheaper than biopsy-based testing.²⁴

Non-invasive PGT-A is not ready for routine clinical use yet. The amount of cfDNA in spent culture medium is low, and contamination from maternal DNA or cumulus cells remains a technical challenge. But progress is steady, and if these methods prove reliable, they could change the mosaic conversation fundamentally: fewer biopsies, fewer ambiguous results, and a clearer view of which embryos truly carry mixed cell populations.

When Clinics Say No

Even when a patient and their doctor agree that a mosaic embryo transfer is reasonable, institutional barriers can get in the way. Some clinics refuse to transfer embryos that PGT-A has flagged as anything other than euploid, a policy driven partly by liability concerns and partly by the performance metrics that clinics report publicly, such as live birth rates per transfer. A mosaic transfer has a lower expected success rate than a euploid one, and clinics that track their outcomes carefully may be reluctant to accept that statistical hit.²⁵ Patients in this situation sometimes transport their embryos to a different facility willing to perform the transfer, adding cost and logistical complexity. The tension between institutional risk management and patient autonomy is one of the less discussed but very real dimensions of the mosaic embryo question, and it affects patients unequally depending on geography, finances, and access to second opinions.

1
PubMed Central. The mechanisms and clinical application of mosaicism in preimplantation embryos
2
Cell Discovery. Human embryos harbor complex mosaicism with broad presence of aneuploid cells during early development
3
PubMed Central. Meiotic and mitotic aneuploidies drive arrest of in vitro fertilized human preimplantation embryos
4
The Journal of Molecular Diagnostics. Next-Generation Sequencing Is More Efficient at Detecting Mosaic Embryos and Improving Pregnancy Outcomes than Single-Nucleotide Polymorphism Array Analysis
5
Human Reproduction. L26/P-645 Chromosome Concordance of Inner Cell Mass (ICM) and Multifocal Trophectoderm (TE) Biopsies: Impact of Biopsy Location, Ploidy Status, and Oocyte Origin
6
PubMed. Chromosomal mosaicism in human blastocysts: a cytogenetic comparison of trophectoderm and inner cell mass after next-generation sequencing
7
PubMed Central. PGT-A mosaicism based on NGS intermediate copy numbers: is it time to stop reporting them?
8
Human Reproduction. Embryonic ploidy correction: an update on mechanisms and insights from mosaic embryo transfer
9
PubMed Central. Healthy Live Births after the Transfer of Mosaic Embryos: Self-Correction or PGT-A Overestimation?
10
PubMed Central. Mosaic embryo transfer-first report of a live born with nonmosaic partial aneuploidy and uniparental disomy 15
11
PubMed Central. Live birth and other reproductive outcomes of mosaic and euploid embryos: a systematic review and meta-analysis
12
PubMed Central. Rates of live birth after mosaic embryo transfer compared with euploid embryo transfer
13
PubMed Central. The Pregnancy Outcome of Mosaic Embryo Transfer: A Prospective Multicenter Study and Meta-Analysis
14
Reproductive BioMedicine Online. What Is a Mosaic Embryo and Should You Transfer One?
15
PubMed Central. Clinical Outcomes of Single Mosaic Embryo Transfer: High-Level or Low-Level Mosaic Embryo, Does It Matter?
16
PubMed. Neonatal and clinical outcomes after transfer of a mosaic embryo identified by preimplantation genetic testing for aneuploidies
17
PubMed. Which type of chromosomal mosaicism is compatible for embryo transfer: a systematical review and meta-analysis
18
Human Reproduction. L26/P-661 Chromosome-specific pregnancy outcomes after mosaic embryo transfer: disentangling abnormality severity from chromosome identity
19
Human Reproduction. O-154 Chromosomal, gestational, and neonatal outcomes of mosaic embryos: analysis of 3074 cases from the international registry of mosaic embryo
20
PubMed Central. ESHRE survey results and good practice recommendations on managing chromosomal mosaicism
21
PubMed Central. Exploration of decision-making regarding the transfer of mosaic embryos following preimplantation genetic testing: a qualitative study
22
PubMed. What are patients doing with their mosaic embryos? Decision making after genetic counseling
23
PubMed Central. An Update on Non-invasive Approaches for Genetic Testing of the Preimplantation Embryo
24
PubMed. Noninvasive preimplantation genetic testing using the embryo spent culture medium: an update
25
Human Reproduction. L26/O-238 Reclaiming possibility: patient perspectives on transferring embryos labeled “abnormal” by PGT-A and the ethical and legal implications